AU2014336389B2 - Pharmaceutical dosage forms containing sodium-1-[6-(morpholin-4-yl)pyrimidin-4-yl]-4-(1H-1,2,3-triazol-1-yl)-1H-pyrazol-5-olate - Google Patents

Pharmaceutical dosage forms containing sodium-1-[6-(morpholin-4-yl)pyrimidin-4-yl]-4-(1H-1,2,3-triazol-1-yl)-1H-pyrazol-5-olate Download PDF

Info

Publication number
AU2014336389B2
AU2014336389B2 AU2014336389A AU2014336389A AU2014336389B2 AU 2014336389 B2 AU2014336389 B2 AU 2014336389B2 AU 2014336389 A AU2014336389 A AU 2014336389A AU 2014336389 A AU2014336389 A AU 2014336389A AU 2014336389 B2 AU2014336389 B2 AU 2014336389B2
Authority
AU
Australia
Prior art keywords
olate
morpholin
triazol
pyrazol
pyrimidin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2014336389A
Other languages
English (en)
Other versions
AU2014336389A1 (en
Inventor
Klaus Benke
Michael Formell
Heike Neumann
Gabriele Winter
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Pharma AG
Original Assignee
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49356354&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2014336389(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG
Publication of AU2014336389A1 publication Critical patent/AU2014336389A1/en
Application granted granted Critical
Publication of AU2014336389B2 publication Critical patent/AU2014336389B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
AU2014336389A 2013-10-17 2014-10-13 Pharmaceutical dosage forms containing sodium-1-[6-(morpholin-4-yl)pyrimidin-4-yl]-4-(1H-1,2,3-triazol-1-yl)-1H-pyrazol-5-olate Ceased AU2014336389B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP13189145.9 2013-10-17
EP13189145 2013-10-17
PCT/EP2014/071855 WO2015055564A1 (de) 2013-10-17 2014-10-13 Pharmazeutische darreichungsformen enthaltend natrium-1-[6-(morpholin-4-yl)pyrimidin-4-yl]-4-(1h-1,2,3-triazol-1-yl)-1h-pyrazol-5-olat

Publications (2)

Publication Number Publication Date
AU2014336389A1 AU2014336389A1 (en) 2016-05-12
AU2014336389B2 true AU2014336389B2 (en) 2020-01-30

Family

ID=49356354

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2014336389A Ceased AU2014336389B2 (en) 2013-10-17 2014-10-13 Pharmaceutical dosage forms containing sodium-1-[6-(morpholin-4-yl)pyrimidin-4-yl]-4-(1H-1,2,3-triazol-1-yl)-1H-pyrazol-5-olate

Country Status (35)

Country Link
US (1) US9827198B2 (de)
EP (1) EP3057580B1 (de)
JP (1) JP6525979B2 (de)
KR (1) KR102330953B1 (de)
CN (1) CN105636580B (de)
AP (1) AP2016009135A0 (de)
AR (1) AR098064A1 (de)
AU (1) AU2014336389B2 (de)
BR (1) BR112016007588A2 (de)
CA (1) CA2927437C (de)
CL (1) CL2016000857A1 (de)
CU (1) CU24515B1 (de)
DK (1) DK3057580T3 (de)
DO (1) DOP2016000078A (de)
EA (1) EA032932B1 (de)
ES (1) ES2868228T3 (de)
GT (1) GT201600072A (de)
HR (1) HRP20210691T1 (de)
HU (1) HUE054107T2 (de)
IL (1) IL244933B (de)
JO (1) JO3645B1 (de)
LT (1) LT3057580T (de)
MA (1) MA38974B2 (de)
MX (1) MX2016004628A (de)
MY (1) MY190202A (de)
NI (1) NI201600054A (de)
PE (1) PE20160669A1 (de)
PH (1) PH12016500716B1 (de)
SA (1) SA516370940B1 (de)
SI (1) SI3057580T1 (de)
TN (1) TN2016000135A1 (de)
TW (1) TWI746418B (de)
UA (1) UA119855C2 (de)
UY (1) UY35784A (de)
WO (1) WO2015055564A1 (de)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3108993C (en) * 2018-08-31 2023-10-17 Astellas Pharma Inc. Pharmaceutical composition for oral administration

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120129857A1 (en) * 2010-11-18 2012-05-24 Bayer Pharma Aktiengesellschaft Substituted sodium 1H-pyrazol-5-olate

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102006050516A1 (de) 2006-10-26 2008-04-30 Bayer Healthcare Ag Substituierte Dihydropyrazolone und ihre Verwendung
EP2133096A4 (de) * 2007-03-13 2011-11-16 Dainippon Sumitomo Pharma Co Im mund zerfallende tablette

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120129857A1 (en) * 2010-11-18 2012-05-24 Bayer Pharma Aktiengesellschaft Substituted sodium 1H-pyrazol-5-olate

Also Published As

Publication number Publication date
MA38974B2 (fr) 2020-11-30
BR112016007588A2 (pt) 2017-09-12
HUE054107T2 (hu) 2021-08-30
CN105636580B (zh) 2020-03-31
TWI746418B (zh) 2021-11-21
NI201600054A (es) 2016-09-21
KR102330953B1 (ko) 2021-11-26
EA201690788A1 (ru) 2016-09-30
WO2015055564A1 (de) 2015-04-23
HRP20210691T1 (hr) 2021-06-11
SI3057580T1 (sl) 2021-07-30
CL2016000857A1 (es) 2016-11-25
DK3057580T3 (da) 2021-05-10
JP2016538256A (ja) 2016-12-08
SA516370940B1 (ar) 2019-11-20
UA119855C2 (uk) 2019-08-27
JO3645B1 (ar) 2020-08-27
TW201607568A (zh) 2016-03-01
UY35784A (es) 2015-05-29
TN2016000135A1 (en) 2017-10-06
EP3057580B1 (de) 2021-02-24
PE20160669A1 (es) 2016-08-04
JP6525979B2 (ja) 2019-06-05
KR20160068784A (ko) 2016-06-15
PH12016500716A1 (en) 2016-06-20
GT201600072A (es) 2018-12-19
NZ718063A (en) 2021-06-25
MX2016004628A (es) 2016-08-01
PH12016500716B1 (en) 2016-06-20
US20160256394A1 (en) 2016-09-08
US9827198B2 (en) 2017-11-28
EA032932B1 (ru) 2019-08-30
CU24515B1 (es) 2021-05-12
AP2016009135A0 (en) 2016-04-30
AR098064A1 (es) 2016-04-27
IL244933B (en) 2020-11-30
CN105636580A (zh) 2016-06-01
CA2927437C (en) 2022-06-28
IL244933A0 (en) 2016-05-31
LT3057580T (lt) 2021-04-12
CU20160048A7 (es) 2016-10-28
DOP2016000078A (es) 2016-08-15
AU2014336389A1 (en) 2016-05-12
EP3057580A1 (de) 2016-08-24
CA2927437A1 (en) 2015-04-23
MA38974A1 (fr) 2017-05-31
ES2868228T3 (es) 2021-10-21
MY190202A (en) 2022-04-04

Similar Documents

Publication Publication Date Title
IL236495A0 (en) Heteroaromatic compounds as proton tyrosine kinase inhibitors
IL247276A0 (en) [1,2,4]-converted triazole and imidazole compounds as fungicides
IL244206A0 (en) A pharmaceutical preparation containing a pyrimidine compound as an active ingredient
EP3036231A4 (de) Substituierte pyrimidinverbindungen sowie zusammensetzungen daraus und medizinische anwendungen damit
EP3138842A4 (de) Als hemmer der bruton-tyrosinkinase wirkende, polyfluorinierte verbindungen
IL249367A0 (en) Altered [4,2,1]triazole compounds
HK1248070A1 (zh) 作為激酶抑制劑的雜環化合物
EP3414234A4 (de) Hemmer der bruton-tyrosinkinase
EP3004061B8 (de) 3,4-dihydroisochinolin-2(1h)-yl-verbindungen
EP3299366A4 (de) Substituierte pyrazolverbindungen mit pyrimidin und herstellungsverfahren und verwendung davon
EP3376865A4 (de) 4-((6-(2,4-difluorphenyl)-1,1-difluor-2-hydroxy-3-(1h
IL249299A0 (en) Modified [4,2,1]triazole and imidazole compounds as fungicides
SG10201507714XA (en) 3,5-diaminopyrazole kinase inhibitors
IL243226A0 (en) History of pyrazole, their preparation and pharmaceutical preparations containing them
EP3073998A4 (de) Pharmazeutische kombinationsformulierung mit amlodipin, losartan und rosuvastatin
EP3076968A4 (de) Ccr6-verbindungen
HK1212337A1 (en) Substituted 5,6-ring-fused naphthopyran compounds 56--
EP3034082A4 (de) Pharmazeutische zusammensetzung zur behandlung oder prävention neuropsychiatrischer krankheiten mit flavon-6-c-glucose-derivaten als wirkstoffen
SG11201507575QA (en) Novel benzenesulfonamide compounds, method for synthesizing same, and use thereof in medicine as well as in cosmetics
ZA201608472B (en) Substituted [1,2,4]triazole and imidazole compounds as fungicides
EP3037092A4 (de) Zusammensetzung mit einer monoacetyldiglyceridverbindung als wirkstoff zur hemmung von blutkrebs oder metastasen
IL243650A0 (en) History of 1-(piperazine-1-yl)-2-([4,2,1]triazol-1-yl)-ethanone
TWI800759B (zh) 醫藥劑型
IL243223A0 (en) History of imidazole, their preparation and pharmaceutical preparations containing them
AU2014340351B2 (en) Fused heterocyclic organic compounds, pharmaceutical compositions, and medical uses thereof

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired